Javascript must be enabled to continue!
P3649Analysis of clinical and angiographic parameters as predictors of recurrent vasospastic angina
View through CrossRef
Abstract
Background
Patients with vasospastic angina (VA) may have recurrent chest symptoms and life-threatening arrhythmias. Despite regular medications, many VA patients experience recurrent episodes of VA. In this study, we evaluate clinical and angiographic predictors of recurrent VA.
Patients and methods
From January 2010 to May 2018, a total of 858 patients who underwent ergonovine provocation test were retrospectively reviewed. We excluded the patients who had negative results of provocation test, follow up duration less than 1 month and poor medication compliance. The recurrent-VA group consisted of patients who were re-hospitalized, visited the emergency room, or had repeated coronary angiographies because of chest pain.
Results
A total of 858 patients who underwent ergonovine provocation tests between January 2010 to May 2018 were retrospectively reviewed. Of them, 162 (mean follow-up duration, 3.0 years) were eligible for our study. The patients were divided into two groups: recurrent-VA (n=33, 20.4%) and stable-VA groups (n=129, 79.6%). Compared with the stable-VA group, the recurrent-VA group consisted mostly of men (93.9% vs. 75.2%, P=0.01), and had low LDL-cholesterol levels (93±27 mg/dl vs. 108±31 mg/dl, P=0.01). In the angiographic findings, a degree of coronary artery disease (CAD) and the site and number of spasm-positive vessels showed no difference between the two groups. Nicorandil was more frequently prescribed at discharge in the stable-VA group (15.2% vs. 35.7%, P=0.02). In the multivariate analysis, the male sex (odds ratio [OR], 5.87; 95% confidence interval [CI], 1.31–26.22; P=0.02) and non-use of nicorandil (OR, 3.51; 95% CI, 1.25–9.84; P=0.01) were the independent predictive factors in the recurrent-VA group. In the Kaplan-Meier analysis, men who did not use nicorandil (n=85, 52.5%) had higher incidences of recurrent angina compared to the other group (n=77, 47.5%). (30.6% vs. 6.6%; p<0.001).
Univariate and multivariate analysis Refractory VA (n=33) Stable VA (n=129) Odds ratio [95% CI] P value univariate Odds ratio [95% CI] P value multivariate Age <56 years, n (%) 20 (66) 58 (44) 1.88 [0.86–4.10] 0.11 NA NS Male sex, n (%) 31 (93.9) 97 (75.2) 5.11 [1.15–22.56] 0.03 5.87 [1.31–26.22] 0.02 Smoking, n (%) 17 (51.5) 46 (35.7) 1.91 [0.88–4.14] 0.09 NA NS No AMI presentation, n (%) 11 (33.3) 25 (19.4) 2.08 [0.89–4.84] 0.08 NA NS Troponin-I >0.86 ng/ml, n (%) 2 (7.1) 3 (2.7) 2.74 [0.43–17.27] 0.08 NA NS LDL-C <105 mg/dl, n (%) 21 (63) 58 (49) 1.81 [0.81–4.01] 0.14 NA NS No use of nicorandil, n (%) 5 (15.2) 46 (35.7) 3.10 [1.12–8.58] 0.02 3.51 [1.25–9.84] 0.01
Kaplan-Meier curves
Conclusions
Male sex and non-use of nicorandil were independent predictors of recurrent VA.
Title: P3649Analysis of clinical and angiographic parameters as predictors of recurrent vasospastic angina
Description:
Abstract
Background
Patients with vasospastic angina (VA) may have recurrent chest symptoms and life-threatening arrhythmias.
Despite regular medications, many VA patients experience recurrent episodes of VA.
In this study, we evaluate clinical and angiographic predictors of recurrent VA.
Patients and methods
From January 2010 to May 2018, a total of 858 patients who underwent ergonovine provocation test were retrospectively reviewed.
We excluded the patients who had negative results of provocation test, follow up duration less than 1 month and poor medication compliance.
The recurrent-VA group consisted of patients who were re-hospitalized, visited the emergency room, or had repeated coronary angiographies because of chest pain.
Results
A total of 858 patients who underwent ergonovine provocation tests between January 2010 to May 2018 were retrospectively reviewed.
Of them, 162 (mean follow-up duration, 3.
0 years) were eligible for our study.
The patients were divided into two groups: recurrent-VA (n=33, 20.
4%) and stable-VA groups (n=129, 79.
6%).
Compared with the stable-VA group, the recurrent-VA group consisted mostly of men (93.
9% vs.
75.
2%, P=0.
01), and had low LDL-cholesterol levels (93±27 mg/dl vs.
108±31 mg/dl, P=0.
01).
In the angiographic findings, a degree of coronary artery disease (CAD) and the site and number of spasm-positive vessels showed no difference between the two groups.
Nicorandil was more frequently prescribed at discharge in the stable-VA group (15.
2% vs.
35.
7%, P=0.
02).
In the multivariate analysis, the male sex (odds ratio [OR], 5.
87; 95% confidence interval [CI], 1.
31–26.
22; P=0.
02) and non-use of nicorandil (OR, 3.
51; 95% CI, 1.
25–9.
84; P=0.
01) were the independent predictive factors in the recurrent-VA group.
In the Kaplan-Meier analysis, men who did not use nicorandil (n=85, 52.
5%) had higher incidences of recurrent angina compared to the other group (n=77, 47.
5%).
(30.
6% vs.
6.
6%; p<0.
001).
Univariate and multivariate analysis Refractory VA (n=33) Stable VA (n=129) Odds ratio [95% CI] P value univariate Odds ratio [95% CI] P value multivariate Age <56 years, n (%) 20 (66) 58 (44) 1.
88 [0.
86–4.
10] 0.
11 NA NS Male sex, n (%) 31 (93.
9) 97 (75.
2) 5.
11 [1.
15–22.
56] 0.
03 5.
87 [1.
31–26.
22] 0.
02 Smoking, n (%) 17 (51.
5) 46 (35.
7) 1.
91 [0.
88–4.
14] 0.
09 NA NS No AMI presentation, n (%) 11 (33.
3) 25 (19.
4) 2.
08 [0.
89–4.
84] 0.
08 NA NS Troponin-I >0.
86 ng/ml, n (%) 2 (7.
1) 3 (2.
7) 2.
74 [0.
43–17.
27] 0.
08 NA NS LDL-C <105 mg/dl, n (%) 21 (63) 58 (49) 1.
81 [0.
81–4.
01] 0.
14 NA NS No use of nicorandil, n (%) 5 (15.
2) 46 (35.
7) 3.
10 [1.
12–8.
58] 0.
02 3.
51 [1.
25–9.
84] 0.
01
Kaplan-Meier curves
Conclusions
Male sex and non-use of nicorandil were independent predictors of recurrent VA.
Related Results
Abstract 4140903: Long-Term Clinical Outcomes in Definite versus Intermediate Ergovonine Provocation response in Multivessel Vasospastic Angina Patients
Abstract 4140903: Long-Term Clinical Outcomes in Definite versus Intermediate Ergovonine Provocation response in Multivessel Vasospastic Angina Patients
Background:
Patients with multivessel coronary spasm showed relatively poor outcomes in vasospastic angina. Recent report also revealed that Ergovonine response definit...
239 VASOSPASTIC ANGINA: A CASE OF COMPLETE FUNCTIONAL ASSESSMENT
239 VASOSPASTIC ANGINA: A CASE OF COMPLETE FUNCTIONAL ASSESSMENT
Abstract
Introduction
Vasospastic angina is defined as a focal or diffuse spasm of the arterial wall of an epicardial coronary a...
NEW CANDIDATE BIOMARKER FOUND IN UNSTABLE ANGINA PATIENTS BY LC-MS/MS
NEW CANDIDATE BIOMARKER FOUND IN UNSTABLE ANGINA PATIENTS BY LC-MS/MS
Objectives
Coronary heart disease (CHD) is the leading cause of death of adults worldwide, but the traditional related factors cannot explain the whole situations...
Abstract 4146122: Potential Protective Roles of Clonal Hematopoiesis of Indeterminate Potential in Angina Pectoris
Abstract 4146122: Potential Protective Roles of Clonal Hematopoiesis of Indeterminate Potential in Angina Pectoris
Introduction:
Clonal hematopoiesis of indeterminate potential (CHIP) poses strong relationship to the occurrence of cardiovascular diseases with the process of aging. I...
Increased Autoantibodies Against Oxidized Low-Density Lipoprotein in Coronary Circulation in Patients with Coronary Spastic Angina
Increased Autoantibodies Against Oxidized Low-Density Lipoprotein in Coronary Circulation in Patients with Coronary Spastic Angina
Oxidized low-density lipoproteins are important in the progression of atherosclerosis. Autoantibodies against malondialdehyde-modified low-density lipoproteins have been reported t...
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Abstract
Introduction
Coronary subclavian steal syndrome (CSSS) is a rare phenomenon that often goes undiagnosed and causes severe complications, including death. This report prese...
Chronic Stable Angina
Chronic Stable Angina
By definition, chronic stable angina is angina that has been stable with regard to frequency and severity for at least 2 months. Chronic stable angina is the initial manifestation ...
GW24-e2942 The change of endogenous asymmetric NG, NG-dimethyl-L-arginine in patients with unstable angina pectoris
GW24-e2942 The change of endogenous asymmetric NG, NG-dimethyl-L-arginine in patients with unstable angina pectoris
Objectives
To investigate the change of asymmetric NG, NG-dimethyl-L-arginine (ADMA) and elucidate the possible mechanism of endothelial dysfunction in patients w...

